Cargando…

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study

The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuyama, Hisayuki, Hakoshima, Mariko, Umeyama, Shohei, Iida, Sakura, Adachi, Hiroki, Yanai, Hidekatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046001/
https://www.ncbi.nlm.nih.gov/pubmed/36979848
http://dx.doi.org/10.3390/biomedicines11030869
_version_ 1785013556535623680
author Katsuyama, Hisayuki
Hakoshima, Mariko
Umeyama, Shohei
Iida, Sakura
Adachi, Hiroki
Yanai, Hidekatsu
author_facet Katsuyama, Hisayuki
Hakoshima, Mariko
Umeyama, Shohei
Iida, Sakura
Adachi, Hiroki
Yanai, Hidekatsu
author_sort Katsuyama, Hisayuki
collection PubMed
description The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the reports of real-world efficacy on metabolic parameters in Japanese patients with type 2 diabetes (T2DM) are limited. This study aimed to examine the real-world efficacy of GLP-1RA dulaglutide on metabolic parameters in Japanese patients with T2DM. We retrospectively selected patients with T2DM who had been prescribed dulaglutide continuously for 12 months or longer between September 2015 and December 2020 and compared metabolic parameters at baseline with the data at 12 months after the start of dulaglutide. One hundred twenty-one patients were enrolled in this study. The 12-month dulaglutide treatment reduced body weight by 1.7 kg and hemoglobin A1c by 1.1%. Significant improvements were also observed in serum high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C. The change in HbA1c during dulaglutide treatment was significantly correlated with the changes in HDL-C (R = −0.236, p = 0.013), LDL-C (R = 0.377, p = 0.005) and non-HDL-C (R = 0.415, p < 0.001). The improvements in HbA1c, HDL-C, TG and non-HDL-C were greater in patients concurrently treated with SGLT2 inhibitors (SGLT2is) at baseline. In conclusion, the treatment with dulaglutide has beneficial effects on multiple CV risk factors in Japanese patients with T2DM.
format Online
Article
Text
id pubmed-10046001
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100460012023-03-29 Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Katsuyama, Hisayuki Hakoshima, Mariko Umeyama, Shohei Iida, Sakura Adachi, Hiroki Yanai, Hidekatsu Biomedicines Article The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to improve body weight and glycemic control and reduce major cardiovascular (CV) events. In Japan, dulaglutide is used at a fixed dose of 0.75 mg, which is lower than that in Europe and North America. However, the reports of real-world efficacy on metabolic parameters in Japanese patients with type 2 diabetes (T2DM) are limited. This study aimed to examine the real-world efficacy of GLP-1RA dulaglutide on metabolic parameters in Japanese patients with T2DM. We retrospectively selected patients with T2DM who had been prescribed dulaglutide continuously for 12 months or longer between September 2015 and December 2020 and compared metabolic parameters at baseline with the data at 12 months after the start of dulaglutide. One hundred twenty-one patients were enrolled in this study. The 12-month dulaglutide treatment reduced body weight by 1.7 kg and hemoglobin A1c by 1.1%. Significant improvements were also observed in serum high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C. The change in HbA1c during dulaglutide treatment was significantly correlated with the changes in HDL-C (R = −0.236, p = 0.013), LDL-C (R = 0.377, p = 0.005) and non-HDL-C (R = 0.415, p < 0.001). The improvements in HbA1c, HDL-C, TG and non-HDL-C were greater in patients concurrently treated with SGLT2 inhibitors (SGLT2is) at baseline. In conclusion, the treatment with dulaglutide has beneficial effects on multiple CV risk factors in Japanese patients with T2DM. MDPI 2023-03-13 /pmc/articles/PMC10046001/ /pubmed/36979848 http://dx.doi.org/10.3390/biomedicines11030869 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Katsuyama, Hisayuki
Hakoshima, Mariko
Umeyama, Shohei
Iida, Sakura
Adachi, Hiroki
Yanai, Hidekatsu
Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
title Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
title_full Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
title_fullStr Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
title_full_unstemmed Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
title_short Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
title_sort real-world efficacy of glucagon-like peptide-1 (glp-1) receptor agonist, dulaglutide, on metabolic parameters in japanese patients with type 2 diabetes: a retrospective longitudinal study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046001/
https://www.ncbi.nlm.nih.gov/pubmed/36979848
http://dx.doi.org/10.3390/biomedicines11030869
work_keys_str_mv AT katsuyamahisayuki realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy
AT hakoshimamariko realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy
AT umeyamashohei realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy
AT iidasakura realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy
AT adachihiroki realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy
AT yanaihidekatsu realworldefficacyofglucagonlikepeptide1glp1receptoragonistdulaglutideonmetabolicparametersinjapanesepatientswithtype2diabetesaretrospectivelongitudinalstudy